Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [BUSINESS]
2 clusters · 2 sources · 29 days · First seen · Last updated
US bank analyst price target upgrades
Overview
In late June 2026, Bank of America lifted its price target for Merck to $141 and analysts simultaneously upgraded Kilroy Realty, indicating a broader willingness among financial institutions to raise expectations for both pharmaceutical and real‑estate stocks.
A month later, in July 2026, JPMorgan Chase & Co. raised its price target for Alkermes to $61, maintaining a neutral rating. The move was echoed by other analysts—UBS, Stifel Nicolaus, Robert W. Baird, and Weiss Ratings—who adjusted their targets and ratings for Alkermes as well. Together, these actions show a continued trend of major U.S. banks and brokerage firms revising upward price targets for pharmaceutical companies, reflecting optimism about sector performance.
Overall, the snapshots illustrate an ongoing pattern where leading U.S. financial analysts periodically reassess and increase valuation metrics for selected pharma stocks, sometimes alongside upgrades in other sectors.
Entities
Stifel Nicolaus · David Joseph Gaffin · Alkermes plc · JPMorgan Chase & Co. · UBS Group
Timeline
-
16 days ago
[BUSINESS] 2 sourcesJPMorgan Raises Alkermes Price Target to $61 Amid Analyst UpgradesJPMorgan raised Alkermes' price target to $61 (neutral rating) as other analysts upgraded ratings; the stock fell to $48.17, with insider David Gaffin selling shares.
-
about 1 month ago
[BUSINESS] 2 sourcesBank of America raises Merck price target to $141 as analysts upgrade Kilroy RealtyBank of America raised Merck's price target to $141 and kept a buy rating, while analysts upgraded Kilroy Realty with higher targets; director Jolie Hunt sold a large portion of her Kilroy shares.
Sources
mommygearest.com · stocknews.com